Delayed Administration of WP1066, an STAT3 Inhibitor, Ameliorates Radiation-Induced Lung Injury in Mice

• DOI: 10.1007/s00408-015-9821-8
• Publication Date: 2015-11-12T23:53:34Z
• Authors: Jiahua Yu; Xiaopeng Yuan; Yang Liu; Kaishuo Zhang; Jie Wang; Haowen Zhang; Fenju Liu
• Keywords: STAT3 Transcription Factor; Interleukin-6; Pyridines; Tumor Necrosis Factor-alpha; Interleukin-1beta; Gene Expression; Tyrphostins; Fibrosis; Drug Administration Schedule; 3. Good health; Mice, Inbred C57BL; Radiation Pneumonitis; Mice; Radiation Injuries, Experimental; 03 medical and health sciences; 0302 clinical medicine; Transforming Growth Factor beta; Animals; Female; RNA, Messenger; Lung; Signal Transduction

The present study was designed to investigate the effects of WP1066, a specific inhibitor of STAT3 signaling, on radiation-induced lung injury in mice.C57BL/6J mice were subjected to a single thoracic irradiation of 15 Gy X-ray and WP1066 was administrated through intraperitoneal injection. The early and delayed treatment groups were treated with WP1066 during the first 2 weeks and the second 2 weeks, respectively. The therapeutic effects of WP1066 were evaluated by survival analysis, histological examination, and measurement of inflammatory parameters and collagen deposition. The activation of STAT3 pathway was also estimated by immunohistochemical staining and Western blotting.Delayed treatment of WP1066, but not early treatment, prolonged survival time and prevented the development of radiation pneumonitis and the subsequent lung fibrosis in mice. WP1066 treatment also significantly suppressed the activation of STAT3 signaling in the irradiated lung tissues.The activation of STAT3 pathway might play an important part in the pathogenesis of radiation-induced lung injury. The protective effects of delayed treatment of WP1066 suggested STAT3 signaling could be a therapeutic target for radiation pneumonitis.